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INTRODUCTION
Although renal transplantation has dramatically
changed the outcome of end stage renal disease, it is
associated with significant side effects including oppor-
tunistic infections, graft rejection, drug toxicity, and
malignancy [1]. The incidence of malignancy after renal
transplant has been reported to range from 4% to 18% and
may result from pre-existing cancers in recipients, donor-
transmitted cancers, or de novo malignancies [2,3].
Other predisposing factors for the development of malig-
nancies include immunosuppressive agents, carcinogenic
effects of medications, activation of oncogenic viruses,
uremia, and antigenic stimulation from the transplant
[3,4]. Tumors of the skin and lip tend to be the most
common, while non-Hodgkin lymphoma comprises 20%
of all neoplasms [3,5]. In this report, we describe a 15-
year-old female who, 9 years after receiving a living
related renal transplant, developed a post-transplant
primitive neuroectodermal tumor (PNET) of the uterus.
CLINICAL HISTORY
A 15-year-old Asian American female with a history
of a renal allograft presented with a 2-day history of
emesis, loose stools, suprapubic abdominal pain, and fever
up to 101.38F. She had also complained of increased
vaginal bleeding for the past 4 months. There was no
history of weight loss, hematuria, or dyspnea though she
did complain of urinary frequency and urgency without
dysuria. She had received a living related donor renal
transplant 9 years previously for end stage renal disease,
secondary to membranoproliferative glomerulonephritis
type I. The post-transplant immunosuppressive therapy
included cyclosporin, Imuran, and corticosteroids. Three
episodes of acute rejection were treated with brief courses
of high dose corticosteroids and one course of OKT3.
On physical examination her temperature was 38.58C,
heart rate was 130, and her blood pressure was normal.
Abdominal examination revealed a 6 cm 7 cm supra-
pubic mass, which was firm, fixed, and tender. There was
no evidence of lymphadenopathy or hepatosplenomegaly.
Urinalysis revealed 50–100WBC, 2þ protein, andwas
positive for leukocyte esterase and nitrates. Both urine and
blood cultures grew Escherichia coli and intravenous
antibiotic therapywas started empirically. Investigation of
the suprapubic mass by ultrasonography and magnetic
radiographic imaging (MRI), revealed a large intrauterine
cystic mass (Figs. 1 and 2). The mass extended into and
through the cervical os, with involvement of bilateral iliac
nodes, suggestive of a uterine malignancy. At laparotomy,
a necrotic mass within the uterus was noted and she
underwent a gross total resection of the tumor including
hysterectomy with lymph node biopsy. Post-operative
imaging revealed no evidence of metastatic disease.
The incidence of malignancy after renal
transplant has been reported to range from 4%
to 18%. Tumors of the skin and lip tend to be the
most common with non-Hodgkin lymphoma
comprising 20% of all neoplasms. Primitive
neuroectodermal tumors (PNET) are collectively
described as being a part of the Ewing sarcoma
family of tumors. PNET occur more commonly
in the second decade of life, predominantly
affecting Whites and Hispanics, and rarely
occur in individuals of African or Asian descent.
The most common primary site of involvement
is along the central axis, particularly the chest
(Askin tumor), but it can arise in any soft tissue.
PNET also occur in the head and neck. PNET
involving the cervix, urinary bladder, uterus,
and vagina have been reported. We describe a
case of a 15-year-old female who, 9 years after
receiving a living related renal transplant,
developed a post-transplant PNET of the uterus.
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Microscopic examination revealed the uterine wall to
be infiltrated by large nests of undifferentiated small round
blue cells. Tumor cells had coarsely granular to stippled
chromatin with a high nuclear to cytoplasmic ratio and
numerous mitotic figures throughout (Figs. 3 and 4).
Immunohistochemical stains revealed the tumor cells to
be intensely immunoreactive for MIC2 protein (CD 99),
a marker for PNET/EWING tumor that identifies
glycoprotein p30/32, vimentin (a soft tissue marker), and
cytokeratin reactivity (a marker for epithelial tissue). The
neoplastic cells were positive for PAS, negative for
pancytokeratin. The tumor showed focal strong positivity
with, synaptophysin (a marker for neurons) and neuron
specific enolase (a marker for nerve tissue), all markers
consistent with PNET. Cytogenetics revealed a der(6). RT-
PCR amplification of mRNA extracted from the tumor
failed to demonstrate the EWS-FLI 1 translocation and
subsequent analysis for the ERG gene on chromosome
21 and the ETV-1 gene on chromosome 7 were also
negative. However, a small percentage of EWS/PNET fail
to show a t(11;22) and der(6) has been reported in a subset
of PNET cases.
She received the first course of chemotherapy consisting
of carboplatin (450 mg/m2 ) and etoposide (200 mg/m2).
This was complicated by deterioration in renal function.
The second course of chemotherapy was complicated
by severe renal, liver, and respiratory failure and pancyto-
penia, which responded to aggressive therapy. Three
weeks later, her renal function returned to baseline with a
serum creatine of 1.5 mg/dl. Repeat radiological imaging
revealed no evidence of tumor. In view of the significant
toxicity she experienced during her first two courses of
Fig. 1. Magnetic radiographic imaging of the pelvis revealing a large
cysticmass in the uterine cavitywithmyometrial invasion and extension
into and through the external cervical os.
Fig. 2. Magnetic radiographic imaging of the pelvis revealing a large
cysticmass in the uterine cavitywithmyometrial invasion and extension
into and through the external cervical os.
Fig. 3. Photomicrograph showing uniform round cells with moder-
ately and small-sized nuclei. (H&E 400). [Color figure can be viewed
in the online issue, which is available at www.interscience.wiley.com.]
Fig. 4. Photomicrograph showing the uterine wall infiltrated by large
nest of undifferentiated round cells. (H & E 100). [Color figure can be
viewed in the online issue, which is available at www.interscience.
wiley.com.]
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chemotherapy, her parents refused all additional therapy.
At follow-up 12 months from her last chemotherapy
treatment, she has stable renal function (BUN 32 mg/dl;
creatine 2.2 mg/dl) and has no radiographic evidence of
tumor recurrence.
DISCUSSION
PNETwas first described by Arthur Purdy Stout in the
early part of this century [7]. It is a highlymalignant tumor
andmicroscopically described as a small round cell tumor
focally arranged as rosettes [10]. PNET are collectively
described as being a part of the Ewing sarcoma family of
tumors [7,8]. PNEToccurs more commonly in the second
decade of life, predominantly affecting Whites and
Hispanics and rarely occurring in individuals of African
or Asian descent [7,8]. The most common primary site of
involvement is along the central axis, particularly the chest
(Askin tumor), but it can arise in any soft tissue [8,9].
PNET also occur in the head and neck. PNET involving
the cervix, urinary bladder, and vagina have also been
reported [10].
The differential diagnoses of small round cell tumor
in our patient included uterine lymphoma, small cell
carcinoma, and PNET/Ewing sarcoma. Post-transplant
PNET of the uterus has not been reported and is rare
in patients of Asian decent. Our patient’s tumor had ex-
tension and invasion into the cervical os and invasion of
the uterinewall, findings, whichwere suggestive of amore
aggressive tumor. PNET tend to have a more aggressive
biological behavior with invasion and infiltration into
the surrounding tissue with distant metastases. At
diagnosis as many as 25% of patients have detectable
metastatic disease to lung, bone, and bone marrow; and
nearly all patients have micrometastases [10,11]. Our
patient did not have any detectable metastatic disease at
the time of diagnosis and her lymph node biopsy was
negative for disease.Althoughour patient’s tumor failed to
demonstrate the t(11;22)(q24;q12) (EWS-FLI 1) translo-
cation by RT-PCR, which is detectable in 85% of PNET
cases, cytogenetics revealed a der(6), which has been
previously reported; immunohistochemistry and micro-
scopic evaluation was consistent with PNET [7].
According to the Cincinnati Transplant Registry
(CTTR), data on 11,359 post-transplant related malig-
nancies have occurred in 10,667 organ allograft recipients
with no reports of post-transplant uterine PNET reported
as of 1998 [13]. The predominant tumors are lymphomas,
carcinomas of the skin, lips, vulva, perineum, and in situ
carcinoma [14]. Excluding Kaposi sarcoma, the incidence
of sarcomawas 1.8%with only one case of Ewing sarcoma
being reported [13]. PNET is a rare tumor comprising 1%
of all sarcomas; it is extremely rare in people of Asian
origin and has not been reported to occur in post-transplant
recipients [5,13]. The predisposing conditions leading to
the development of PNET is unclear, although immuno-
suppression might have been a contributing factor.
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